Minnesota Oncology Hematology PA

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer3 trials
• Lung cancer2 trials
• Ovarian cancer2 trials
• Prostate cancer2 trials
• Bladder cancer1 trial
• Colorectal cancer1 trial
• Endometrial cancer1 trial
• Head and neck cancer1 trial
• Melanoma1 trial

Phase

• Phase 37 trials
• Phase 23 trials
• Phase 11 trial

Status

• Active, not recruiting5 trials
• Completed3 trials
• Recruiting3 trials

Lead sponsor

• Seagen, a wholly owned subsidiary of Pfizer4 trials
• Eli Lilly and Company3 trials
• Amgen2 trials
• Daiichi Sankyo1 trial
• Verastem, Inc.1 trial

Running trials

• Recruiting

  A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  NCT07213674· Phase 3· Amgen· Source

• Recruiting

  Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  NCT06819007· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

  NCT05911295· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Recruiting

  A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

  NCT05253651· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

  NCT05288166· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

  NCT04625270· Phase 2· Verastem, Inc.· Source

• Active, not recruiting

  A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

  NCT04188548· Phase 1· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

  NCT02107703· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer1 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

  NCT04609566· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Completed

  A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

  NCT04539938· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Completed

  Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

  NCT04303780· Phase 3· Amgen· Source